Search the Newsreel

How Investors Are Reacting To Genmab (CPSE:GMAB) Epcoritamab’s Phase 3 Overall-Survival Miss in DLBCL

Genmab's epcoritamab Phase 3 trial for diffuse large B-cell lymphoma (DLBCL) did not meet its primary overall survival endpoint in the US, impacting the drug's investment narrative for this indication. However, the drug, now branded as TEPKINLY, recently received European approval for follicular lymphoma, …

Genmab (CPSE:GMAB) Could Be 22% Below Fair Value On EPCORE Trial Update

Genmab (CPSE:GMAB) is currently valued at DKK1,858.5, which is 22.3% below its fair value of DKK2,392.08, despite the recent news that its Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its primary endpoint for overall survival in the U.S. The company's recent …

Earnings Preview: Genmab to Report Financial Results on August 06

This article provides a preview of Genmab's upcoming financial results, which are scheduled to be reported on August 06. It anticipates that the report will include key financial metrics and potentially an outlook from the company.

Nordic Earnings Week Kicks Off With Novo Nordisk In Focus

The Nordic earnings season is commencing, with pharmaceutical giant Novo Nordisk set to report its Q2 results on August 5th, and Genmab following on August 6th. The timing of these releases—before market open for Novo Nordisk and after close for Genmab—will influence how their …

Genmab A/S (GMAB) Institutional Confidence

Genmab A/S (GMAB) has an institutional shareholding score of 3.00, placing it 192nd among 384 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 13.72% quarter-over-quarter to 12.10%. James Simons is the largest institutional shareholder, holding 0.72% of outstanding …

Genmab A/S (GMAB) Projected to Announce Earnings on Thursday

Genmab A/S (GMAB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Genmab A/S (GMAB), noting its current valuation score of 9.22, ranking it 48th in the Biotechnology & Medical Research industry. The company's P/E ratio is 21.48, which is slightly below its recent high but significantly above its …

Genmab A/S (GMAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Genmab A/S (GMAB), focusing on its support and resistance levels, various technical indicators, and moving averages. While the stock's price momentum score is low within its industry, its current trading range suggests suitability for range-bound swing trading. …

Genmab's DARZALEX royalties boost H1 sales to $8.17B, signaling strong full-year growth potential.

Genmab reported strong first-half results, with DARZALEX sales reaching $8.17 billion, already exceeding half of its $16 billion full-year target. If second-half sales remain consistent, the company is on track to surpass its full-year guidance with total projected sales of $16.59 billion, further boosted …

Genmab's H1 Preview: Darzalex Beats The Sales Outlook

GMAB|Genmab A/S|Price:28.805|Chg%:-0.065

This article provides a comprehensive stock analysis of Genmab A/S (GMAB) highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite positive analyst ratings and a forecasted upward trend, the technicals currently suggest a sideways trading …

AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its …

Genmab A/S Revenue Breakdown – FWB:GE9

Genmab A/S (FWB:GE9) generated 3.17 billion EUR in revenue last year, with its Antibody Therapeutics segment contributing the most at 3.29 billion EUR. The largest regional contribution came from Denmark, accounting for 2.94 billion EUR. The article provides a high-level overview of the company's …

Genmab (GMAB) Receives a Hold from Morgan Stanley

Morgan Stanley analyst Judah Frommer assigned a Hold rating to Genmab (GMAB) with a price target of $33.00. This follows a recent upgrade to Buy from Hold by TD Cowen. Genmab reported quarterly revenue of $899.32 million and a net profit of $53.2 million, …

Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint

Genmab and AbbVie issued a clarification regarding their Phase 3 EPCORE DLBCL-1 trial, stating that overall survival was the sole U.S. primary endpoint and it was not met. This clarification was deemed necessary due to interpretive ambiguity in earlier disclosures, highlighting the complexities of …

Genmab & AbbVie's Epcoritamab Fails To Meet Primary Goal In Phase 3 EPCORE DLBCL-1 Trial

(RTTNews) - Genmab A/S (GMAB) and AbbVie Inc. (ABBV) on Thursday announced that the Phase 3 EPCORE DLBCL-1 trial evaluating Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) failed to meet its U.S. primary endpoint of overall survival (OS). …

Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Genmab and AbbVie announced that their lymphoma drug, epcoritamab, did not meet the primary endpoint in a Phase 3 clinical trial. The trial aimed to evaluate the drug's efficacy in patients with diffuse large B-cell lymphoma (DLBCL). This outcome is a setback for the …

Genmab stock trades steadily as investors weigh recent earnings and oncology pipeline momentum

Genmab A/S stock is maintaining a steady trade as investors analyze the company's recent strong revenue growth from its antibody-driven oncology treatments and its positive profitability trends. The biotechnology company balances its established commercial products with significant investment in its pipeline of clinical-stage oncology …

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie clarified that overall survival (OS) was the sole U.S. primary endpoint for the Phase 3 EPCORE DLBCL-1 trial, which unfortunately did not meet this endpoint, indicating no statistically significant improvement in OS. The study evaluated epcoritamab in adults with relapsed or …

GMAB Upgraded by TD Cowen -- Price Target Raised to $43.00

TD Cowen has upgraded Genmab (GMAB) from Hold to Buy, significantly increasing its price target from $32.00 to $43.00. This upgrade signals a positive outlook on the biopharmaceutical company's growth and market position. GuruFocus assesses GMAB as 17.7% undervalued with a strong GF Score …

TD Cowen upgrades Genmab to buy (hold) - BN

TD Cowen has upgraded Genmab (GMAB) stock from a "Hold" to a "Buy" rating. The firm also increased its price target for Genmab shares to $43 from $32. This upgrade reflects a more optimistic outlook on the biotechnology company's future performance.

TD Cowen upgrades Genmab stock rating on drug pipeline confidence

TD Cowen upgraded Genmab A/S to Buy from Hold and raised its price target to $43.00 due to confidence in the company's drug pipeline, specifically Epkinly, Rina-S, and peto, which are expected to offset the Darzalex patent cliff. The firm believes the stock is …

Genmab stock holds after recent earnings and pipeline updates

Genmab's stock performance reflects its latest financial results and pipeline developments, with the company reporting increased revenue and operating profit for 2025. The company's cash generation and improved operating margin highlight its financial health, while its valuation remains heavily linked to its antibody pipeline …

Goldman Sachs raises Genmab price target to 2,350 Danish kroner (2,300), reiterates buy - BN

Goldman Sachs has increased its price target for Genmab A/S to 2,350 Danish kroner from the previous 2,300, while maintaining a "buy" rating on the stock. This update reflects the firm's continued confidence in the biotechnology company specializing in cancer treatments and other therapeutic …

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Genmab A/S announced that worldwide net trade sales of its drug DARZALEX (daratumumab), including the subcutaneous product DARZALEX FASPRO®, totaled USD 4,207 million in the second quarter of 2026. The sales were split with USD 2,435 million in the U.S. and USD 1,772 million …

Generation Mining Ltd. Actuals & Estimates (TSX:GENM)

Generation Mining nears $1B copper project funding

Canada Infrastructure Bank backs Generation Mining with CAD $200M

Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report

Genmab plunges after financial report: Analyst cites uncertainty surrounding clinical trials

Earnings call transcript: Genmab Q1 2026 highlights strong growth, mixed stock reaction

Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook

Here's Why We're Not Too Worried About Generation Mining's (TSE:GENM) Cash Burn Situation

Genmab AS (NASDAQ: GMAB) Share Price, GMAB Stock News, GMAB Share Price & Updates

Genting Malaysia Berhad (KLSE:GENM) Takes On Some Risk With Its Use Of Debt

Generation Mining Limited (GENM.TO) Stock Price, News, Quote & History